Anna Pasetto
- Director of ACT, Associate Professor; PhD
I joined the Oslo University Hospital in 2022 as Director of the Center for Advanced Cell Therapy (ACT) and also Associate Professor at the University of Oslo. Since 2018, I worked at the Karolinska Institutet as Assistant Professor and Managing Director of the pre-GMP facility in the Department of Laboratory Medicine, where I am still affiliated to this day as research specialist.
I received my Master Degree in Molecular Biotechnology in 2007 from Alma Mater Studiorum Bologna University, Italy. I then moved to the Karolinska Institutet where I received my PhD in 2012. I joined the laboratory of Dr. Steven Rosenberg as post-doctoral fellow at the National Cancer Institute, NIH in 2013 and my research was focused on the isolation of TCR genes from mutation-reactive tumor infiltrating lymphocytes in metastatic solid cancers.
My professional goal is to facilitate and support the development of new immunotherapies against cancer.
Publications 2024
Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma
NPJ Precis Oncol, 8 (1), 26
DOI 10.1038/s41698-024-00506-z, PubMed 38302615
Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease
Mol Ther, 32 (2), 540-555
DOI 10.1016/j.ymthe.2024.01.007, PubMed 38213030
Publications 2023
Editorial: Personalized immunotherapy for cancer
Front Oncol, 13, 1171907
DOI 10.3389/fonc.2023.1171907, PubMed 36959783
Publications 2022
Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
Gut, 72 (6), 1186-1195
DOI 10.1136/gutjnl-2022-327216, PubMed 35977815
Cancer genes disfavoring T cell immunity identified via integrated systems approach
Cell Rep, 40 (5), 111153
DOI 10.1016/j.celrep.2022.111153, PubMed 35926468
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer
Int J Mol Sci, 23 (15)
DOI 10.3390/ijms23158590, PubMed 35955721
T-Cell Repertoire Characterization
Methods Mol Biol, 2574, 209-219
DOI 10.1007/978-1-0716-2712-9_9, PubMed 36087203
Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell Products
Front Immunol, 13, 896242
DOI 10.3389/fimmu.2022.896242, PubMed 35784320
Publications 2021
Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections
J Infect Dis, 223 (1), 128-138
DOI 10.1093/infdis/jiaa036, PubMed 31994701
Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy
Cancers (Basel), 13 (17)
DOI 10.3390/cancers13174334, PubMed 34503144
Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells
J Immunother, 44 (1), 1-8
DOI 10.1097/CJI.0000000000000342, PubMed 33086340
Single-Cell TCR and Transcriptome Analysis: An Indispensable Tool for Studying T-Cell Biology and Cancer Immunotherapy
Front Immunol, 12, 689091
DOI 10.3389/fimmu.2021.689091, PubMed 34163487
Publications 2020
Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies
Cells, 9 (6)
DOI 10.3390/cells9061471, PubMed 32560123
Identification and Clinical Application of Immunological Receptors Targeting Mutated Antigens Expressed by Solid Tumors
Cancers (Basel), 12 (10)
DOI 10.3390/cancers12102818, PubMed 33007884
Liver, Tumor and Viral Hepatitis: Key Players in the Complex Balance Between Tolerance and Immune Activation
Front Immunol, 11, 552
DOI 10.3389/fimmu.2020.00552, PubMed 32292409
Publications 2019
Tumor-infiltrating human CD4+ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity
Sci Immunol, 4 (31)
DOI 10.1126/sciimmunol.aao4310, PubMed 30635355
Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients
Nat Commun, 10 (1), 449
DOI 10.1038/s41467-019-08304-z, PubMed 30683863
Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes
J Clin Invest, 129 (11), 4992-5004
DOI 10.1172/JCI127967, PubMed 31609250
Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
Cancer Immunol Res, 7 (4), 534-543
DOI 10.1158/2326-6066.CIR-18-0686, PubMed 30709841
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
J Clin Invest, 129 (3), 1109-1114
DOI 10.1172/JCI123791, PubMed 30714987
Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers
Cancer Discov, 9 (8), 1022-1035
DOI 10.1158/2159-8290.CD-18-1494, PubMed 31164343
Editorial: HBV-the naked truth?
Aliment Pharmacol Ther, 50 (8), 963-964
DOI 10.1111/apt.15428, PubMed 31591767
Publications 2018
T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers
Clin Cancer Res, 24 (22), 5562-5573
DOI 10.1158/1078-0432.CCR-18-0573, PubMed 29853601
Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy
JCI Insight, 3 (19)
DOI 10.1172/jci.insight.122467, PubMed 30282837
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
Nat Med, 24 (6), 724-730
DOI 10.1038/s41591-018-0040-8, PubMed 29867227
Publications 2017
Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties
J Virol, 91 (9)
DOI 10.1128/JVI.00010-17, PubMed 28228595
Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
Science, 356 (6334), 200-205
DOI 10.1126/science.aak9510, PubMed 28408606
Publications 2016
A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma
Clin Cancer Res, 23 (2), 351-362
DOI 10.1158/1078-0432.CCR-16-0906, PubMed 28093487
Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System
Mol Ther, 24 (6), 1078-1089
DOI 10.1038/mt.2016.51, PubMed 26945006
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
Nat Med, 22 (4), 433-8
DOI 10.1038/nm.4051, PubMed 26901407
Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
Clin Cancer Res, 23 (10), 2491-2505
DOI 10.1158/1078-0432.CCR-16-2680, PubMed 27827318
Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor
Cancer Immunol Res, 4 (9), 734-43
DOI 10.1158/2326-6066.CIR-16-0001, PubMed 27354337
Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens
Cancer Immunol Res, 4 (8), 669-78
DOI 10.1158/2326-6066.CIR-15-0215, PubMed 27312342
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
N Engl J Med, 375 (23), 2255-2262
DOI 10.1056/NEJMoa1609279, PubMed 27959684
Publications 2013
A synthetic codon-optimized hepatitis C virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T cell responses in wild-type and NS5A-transgenic mice
J Immunol, 190 (3), 1113-24
DOI 10.4049/jimmunol.1201497, PubMed 23284053
The adjuvant activity of alphavirus replicons is enhanced by incorporating the microbial molecule flagellin into the replicon
PLoS One, 8 (6), e65964
DOI 10.1371/journal.pone.0065964, PubMed 23785460
Functional attributes of responding T cells in HCV infection: the recent advances in engineering functional antiviral T cells
Arch Immunol Ther Exp (Warsz), 62 (1), 23-30
DOI 10.1007/s00005-013-0248-8, PubMed 23955531
Publications 2012
TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity
J Immunol, 189 (9), 4510-9
DOI 10.4049/jimmunol.1201613, PubMed 23024278
Publications 2011
Generation of T-cell receptors targeting a genetically stable and immunodominant cytotoxic T-lymphocyte epitope within hepatitis C virus non-structural protein 3
J Gen Virol, 93 (Pt 2), 247-258
DOI 10.1099/vir.0.037903-0, PubMed 22071510